Browse our 650+ Publications​

Latest Publications

Early peripheral blood and bone marrow MRD as prognostic markers in quadruplet‐treated multiple myeloma without transplant

Derman BA, et al.
Hemasphere
August 2025
Authors and Affiliates
Benjamin A. Derman1 | Jennifer Cooperrider1 | Anna Pula1,2 | Heidi Simmons3 | Tadeusz Kubicki1,4 | Jeffrey Zonder5 | Aimaz Afrough6 | David Grinblatt7 | Jacalyn Rosenblatt8 | Larry D. Anderson Jr.6 | Andrew Kin5 | David Avigan6 | Sunil Narula1 | Shayan Rayani1 | Ken Jiang1 | Ajay Major9 | Theodore Karrison1 | Allison Jacob3 | Andrzej J. Jakubowiak1 1University of Chicago, Chicago, Illinois, USA 2Department of Hematology, Medical University of Lodz, Łódź, Poland 3Adaptive Biotechnologies, Seattle, Washington, USA 4Poznan University of Medical Sciences, Poznan, Poland 5Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, USA 6Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, USA 7Endeavor Health, Evanston, Illinois, USA 8Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA 9University of Colorado, Denver, Colorado, USA

Carfilzomib–lenalidomide–dexamethasone versus lenalidomide–dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label, multicentre, phase 3 trial

Bringhen S, et al.
Lancet Haematology
August 2025
Authors and Affiliates
Sara Bringhen, Lorenzo Cani, Elisabetta Antonioli, Daniele Derudas, Francesca Fazio, Alessandra Larocca, Sonia Ronconi, Claudia Cellini, Antonietta Pia Falcone, Fabrizio Accardi, Anna Marina Liberati, Piero Galieni, Angelo Belotti, Anna Maria Cafro, Roberto Ria, Giulia Benevolo, Iolanda Donatella Vincelli, Donato Mannina, Flavia Lotti, Benedetto Bruno, Vincenzo Marasco, Rita Mazza, Patrizia Tosi, Elena Rivolti, Mario Boccadoro, Mattia D’Agostino SSD Clinical Trial in Oncoematologia e Mieloma Multiplo, Department of Oncology, AOU Città della Salute e della Scienza di Torino, University of Torino, Torino, Italy (S Bringhen MD PhD, G Benevolo MD); Division of Hematology, AOU Città della Salute e della Scienza di Torino, University of Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy (L Cani MD, A Larocca MD PhD, Prof B Bruno MD PhD, M D’Agostino MD); UO Ematologia, AOU Careggi, Firenze, Italy (E Antonioli MD); SC di Ematologia e CTMO, Ospedale Oncologico di Riferimento Regionale “A Businco”, ARNAS “G Brotzu”, Cagliari, Italy (D Derudas MD); Azienda Ospedaliero- Universitaria Policlinico Umberto I, Hematology, Department of Translational and Precision Medicine, Sapienza University, Roma, Italy (F Fazio MD PhD); IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy (S Ronconi MD); AUSL Romagna, Ospedale Santa Maria delle Croci, Ravenna, Italy (C Cellini MD PhD); Hematology, IRCCS “Casa Sollievo della Sofferenza” Hospital, San Giovanni Rotondo, Italy (A P Falcone MD PhD); UOC di Oncoematologia, Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello, Palermo, Italy (F Accardi MD PhD); AO Santa Maria di Terni, Università degli Studi di Perugia, Perugia–Terni, Italy (Prof A M Liberati MD); UOC Ematologia e Terapia cellulare, Ospedale C e G Mazzoni, Ascoli Piceno, Italy (P Galieni MD); Department of Hematology, ASST Spedali Civili di Brescia, Brescia, Italy (A Belotti MD); SC Ematologia, ASST GOM Niguarda, Milano, Italy (A M Cafro MD); University of Bari Aldo Moro Medical School, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), Bari, Italy (Prof R Ria MD); Hematology Unit, Department of Hemato- Oncology and Radiotherapy, Grande Ospedale Metropolitano “Bianchi- Melacrino-Morelli”, Reggio Calabria, Italy (I D Vincelli MD); Oncology-Hematology Department, Papardo Hospital, Messina, Italy (D Mannina MD); Sezione di Ematologia e Immunologia Clinica, Ospedale Santa Maria della Misericordia, località Sant’Andrea delle Fratte, Perugia, Italy (F Lotti MD PhD); Hematology Division, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy (V Marasco MD); Department of Oncology and Hematology, IRCCS Humanitas Research Hospital, Rozzano, Milano, Italy (R Mazza MD); UO Ematologia, Ospedale di Rimini, Rimini, Italy (P Tosi MD); Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy (E Rivolti MD); European Myeloma Network, Italy (Prof M Boccadoro MD)

Safety and Efficacy of Elranatamab in Patients with Relapsed and/or Refractory immunoglobulin Light-Chain Amyloidosis

Vianna P, et al.
Blood
July 2025
Authors and Affiliates
Pedro Vianna1,2,3, Rajshekar Chakraborty4, Shahrier Hossain2, Divaya Bhutani4, Shannon Miller2, Annemarie Rossi2, Sarah A. M. Cuddy3,5, Rodney H. Falk3,5, Suzanne Lentzsch4, Jacob Laubach2,3, Giada Bianchi1,2,3* 1Amyloidosis Program, Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. 3Harvard Medical School, Boston, MA; 4Division of Hematology-Oncology, Columbia University Irving Medical Center, New York, NY, 5Amyloidosis Program, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial

Hungria V, et al.
Lancet Oncology
July 2025
Authors and Affiliates
Vania Hungria, Paweł Robak, Marek Hus, Vera Zherebtsova, Christopher Ward, P Joy Ho, Roman Hájek, Kihyun Kim, Sebastian Grosicki, Hanlon Sia, Adam Bryant, Marcelo Pitombeira de Lacerda, Gracia Aparecida Martinez, Anna Sureda Balarí, Irwindeep Sandhu, Claudio Cerchione, Peter Ganly, Meletios A Dimopoulos, Chengcheng Fu, Mamta Garg, Al-Ola Abdallah, Moshe E Gatt, Albert Oriol Rocafiguera, Michele Cavo, Robert Rifkin, Tomoaki Fujisaki, Michał Mielnik, Joseph Ficek, Alejandro Mantero, Nick Pirooz, Sybil Varghese, Joe Lee, Astrid McKeown, Rachel Rogers, Hena Baig, Lydia Eccersley, Sumita Roy-Ghanta, Pralay Mukhopadhyay, Jacqueline Nielsen, Joanna Opalinska, María-Victoria Mateos, on behalf of the DREAMM-7 study investigators Clinica São Germano, São Paulo, Brazil (V Hungria MD); Medical University of Łódź, Łódź, Poland (Prof P Robak MD); Samodzielny Publiczny Szpital Kliniczny, Lublin, Poland (Prof M Hus MD, M Mielnik MD); Gorodskaya Klinicheskaya Bol’nitsa Im Sp Botkina, Moscow, Russia (V Zherebtsova MD); Royal North Shore Hospital, Sydney, NSW, Australia (Prof C Ward MD); Royal Prince Alfred Hospital, Camperdown, NSW, Australia (Prof P J Ho MBBS); University Hospital Ostrava and University of Ostrava, Ostrava, Czech Republic (Prof R Hájek MD); Sungkyunkwan University, Samsung Medical Center, Seoul, South Korea (Prof K Kim MD); Medical University of Silesia, Katowice, Poland (Prof S Grosicki MD); Pindara Private Hospital, Gold Coast, QLD, Australia (H Sia MBBS); Liverpool Hospital, Sydney, NSW, Australia (A Bryant PhD); Universidade da Região de Joinville and Centro de Hematologia e Oncologia, Joinville, Santa Catarina, Brazil (Prof M Pitombeira de Lacerda MD); Hospital das Clínicas and Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brazil (G A Martinez MD); Institut Català d’Oncologia- L’Hospitalet L.-Barcelona, Barcelona, Spain (A Sureda Balarí MD); Cross Cancer Institute, Edmonton, AB, Canada (I Sandhu MD); Hematology Unit, Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” - IRST IRCCS, Meldola, Forlì-Cesena, Italy (C Cerchione MD); Christchurch Hospital, Christchurch, New Zealand (P Ganly PhD); School of Medicine, National and Kapodistrian University of Athens, Athens, Greece (Prof M A Dimopoulos MD); Korea University, Seoul, South Korea (Prof M A Dimopoulos); The First Affiliated Hospital of Soochow University, Jiangsu, China (Prof C Fu MD); University Hospitals of Leicester NHS Trust, Leicester, UK (M Garg MD); University of Kansas Cancer Center, Fairway, KS, USA (A-O Abdallah MD); Department of Haematology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel (M E Gatt MD); Institut Català d’Oncologia and Josep Carreras Research Institute, Hospital Germans Trias i Pujol, Badalona, Spain (A Oriol Rocafiguera MD); Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy (Prof M Cavo MD); Rocky Mountain Cancer Centers— Denver—Midtown, Denver, CO, USA (R Rifkin MD); Matsuyama Red Cross Hospital, Matsuyama, Japan (T Fujisaki MD); GSK, Collegeville, PA, USA (J Ficek PhD, A Mantero PhD, N Pirooz MHA, S Varghese MBBS, R Rogers MS, S Roy-Ghanta MD, P Mukhopadhyay PhD, J Opalinska MD); GSK, London, UK (J Lee PhD, L Eccersley PhD); GSK, Stevenage, UK (A McKeown PhD); GSK, Mississauga, ON, Canada (H Baig BS); GSK, Chicago, IL, USA (J Nielsen PhD); Instituto de Investigación Biomédica de Salamanca, Hospital Universitario de Salamanca– IBSAL–CIC–Ciberonc, Salamanca, Spain (M-V Mateos MD)

Subcutaneous epcoritamab monotherapy in Japanese patients with relapsed or refractory follicular lymphoma: primary results of the EPCORE NHL-3 trial

Izutsu K, et al.
Leukemia Lymphoma
July 2025
Authors and Affiliates
Koji Izutsua, Daigo Akahaneb, Tomomi Toubaic, Toko Saitod, Yuko Mishimae, Tomoaki Fujisakif, Momoko Nishikorig, Takahiro Kumodeh, Youko Suehiroi, Kenji Ishitsukaj, Rebekah Conlonk, Ami Takahashil, Barbara D’Angelo Månssonm, Elena Favarom and Noriko Fukuharan aDepartment of Hematology, National Cancer Center Hospital, Tokyo, Japan; bDepartment of Hematology, Tokyo Medical University, Tokyo, Japan; cDepartment of Internal Medicine III, Division of Hematology and Cell Therapy, Yamagata University Faculty of Medicine, Yamagata, Japan; dDepartment of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan; eDepartment of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan; fDepartment of Hematology, Japan Red Cross Society, Matsuyama Red Cross Hospital, Matsuyama, Japan; gDepartment of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan; hDepartment of Hematology and Rheumatology, Kindai University, Osaka, Japan; iDepartment of Hematology and Cell Therapy, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; jDepartment of Hematology and Rheumatology, Kagoshima University, Kagoshima, Japan; kAbbVie, North Chicago, IL, USA; lGenmab, Tokyo, Japan; mGenmab, Copenhagen, Denmark; nDepartment of Hematology, Tohoku University, Sendai, Japan

Venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed or refractory multiple myeloma (BELLINI): final overall survival results from a randomised, phase 3 study

Kumar S, et al.
Lancet Haematology
June 2025
Authors and Affiliates
Shaji K Kumar, Simon J Harrison, Michele Cavo, Javier de la Rubia, Rakesh Popat, Cristina Gasparetto, Vania Hungria, Hans Salwender, Kenshi Suzuki, Inho Kim, Maika Onishi, Grace Ku, Rajvineeth Pothacamury, Muhammad Jalaluddin, Jiewei Zeng, Jeremy A Ross, Edyta Dobkowska, Philippe Moreau Mayo Clinic, Rochester, MN, USA (Prof S K Kumar MD); Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia (Prof S J Harrison PhD); Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia (Prof S J Harrison); IRCCS Azienda Ospedaliero- Universitaria di Bologna, Seragnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy (Prof M Cavo MD); Hematology Service Hospital La Fe, IIS La Fe, and School of Medicine and Dentistry, Catholic University of Valencia, Valencia, Spain (Prof J de la Rubia MD); University College London Hospitals NHS Foundation Trust, London, UK (R Popat FRCPath); Duke University Medical Center, Durham, NC, USA (Prof C Gasparetto MD); Clinica São Germano, São Paulo, Brazil (Prof V Hungria MD); Asklepios Tumorzentrum Hamburg, AK Altona and AK St Georg, Hamburg, Germany (H Salwender MD); Japanese Red Cross Medical Center, Tokyo, Japan (Prof K Suzuki MD); Seoul National University, Seoul, South Korea (Prof I Kim MD); Genentech, Inc, South San Francisco, CA, USA (M Onishi MD, G Ku MD); AbbVie, North Chicago, IL, USA (R Pothacamury MD, M Jalaluddin PhD, J Zeng PhD, J A Ross PhD); AbbVie, Schaffhausen, Switzerland (E Dobkowska MD); University Hospital Hôtel-Dieu, Nantes, France (Prof P Moreau MD)

Measurable Residual Disease-Guided Therapy in Newly Diagnosed Myeloma

Perrot A, et al.
June 2025
Authors and Affiliates
Aurore Perrot, M.D.,1 Jérôme Lambert, Ph.D.,2 Cyrille Hulin, M.D.,3 Andrea Pieragostini, M.D.,4 Lionel Karlin, M.D.,5 Bertrand Arnulf, M.D.,6 Philippe Rey, M.D.,7 Laurent Garderet, M.D.,8 Margaret Macro, M.D.,9 Martine Escoffre‑Barbe, M.D.,10 Julie Gay, M.D.,11 Thomas Chalopin, M.D.,12 Romain Gounot, M.D.,13 Jean‑Marc Schiano, M.D.,14 Mohamad Mohty, M.D.,15 Xavier Leleu, M.D.,16 Salomon Manier, M.D.,17 Clara Mariette, M.D.,18 Carine Chaleteix, M.D.,19 Thorsten Braun, M.D.,20 Bernard De Prijck, M.D.,21 Hervé Avet‑Loiseau, M.D.,22 Jean‑Yves Mary, Ph.D.,2 Jill Corre, Pharm.D.,22 Philippe Moreau, M.D.,23 and Cyrille Touzeau, M.D.23 1 Service Hématologie, Hôpital Universitaire de Toulouse Oncopole, Université de Toulouse, Toulouse, France; 2 Biostatistics and Medical Information Department, Hôpital St. Louis, Paris; 3 Service d’Hématologie, Hôpital Haut Lévêque, Centre Hospitalier Universitaire (CHU) de Bordeaux, Pessac, France; 4 Service Hématologie, Hôpital Universitaire de Dijon, Dijon, France; 5 Service Hématologie, Hôpital Universitaire Lyon Sud, Pierre-Bénite, France; 6 Hôpital Universitaire St. Louis, Assistance Publique–Hôpitaux de Paris (AP-HP), Paris; 7 Centre Léon Bérard, Lyon, France; 8 Service Hématologie, Hôpital Universitaire Pitié-Salpêtrière, AP-HP, Paris; 9 Service Hématologie, Institut Hématologie de Basse Normandie, Hôpital Universitaire de Caen, Caen, France; 10 Service Hématologie, Hôpital Universitaire de Rennes, Rennes, France; 11 Hôpital de Bayonne, Bayonne, France; 12 Service Hématologie, Hôpital Universitaire de Tours, Tours, France; 13 Service Hématologie, Hôpital Henri Mondor, Créteil, France; 14 Service Hématologie, Institut Paoli- Calmettes, Marseille, France; 15 Service Hématologie, Hôpital Universitaire St. Antoine, AP-HP, Université Sorbonne, Paris; 16 Service Hématologie, Hôpital Universitaire de Poitiers, Poitiers, France; 17 Service Hématologie, Hôpital Universitaire de Lille, Lille, France; 18 Service Hématologie, Hôpital CHU de Grenoble, Grenoble, France; 19 Service Hématologie, Hôpital Universitaire de Clermont-Ferrand, Clermont-Ferrand, France; 20 Service Hématologie, Hôpital Avicenne, AP-HP, Paris; 21 Service Hématologie, Hôpital Universitaire de Liège, Liège, Belgium; 22 Unité Génomique du Myélome, Hôpital Universitaire de Toulouse Oncopole, Université de Toulouse, Toulouse, France; 23 Service Hématologie, Hôpital Universitaire

Minimal residual disease measurement in blood by mass spectrometry identifies long-term responders in multiple myeloma

Kubicki T, et al.
Blood Neoplasia
June 2025
Authors and Affiliates
Tadeusz Kubicki,1,2 Benjamin A Derman,1 Jennifer H Cooperrider,1 Anna Puła,1,3 David Barnidge,4 Dominik Dytfeld,2 Ken Jiang,1 Andrzej J Jakubowiak1 1University of Chicago, Chicago, Illinois, USA; 2Poznan University of Medical Sciences, Poznan, Poland; 3 Medical University of Lodz, Lodz, Poland 4Binding Site, part of Thermo Fisher, Rochester, NY, USA

Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma

Jagannath S, et al
J Clin Oncol
June 2025
Authors and Affiliates
Sundar Jagannath, MD, FASCO1 ; Thomas G. Martin, MD2; Yi Lin, MD, PhD3 ; Adam D. Cohen, MD4 ; Noopur Raje, MD5 ; Myo Htut, MD6; Abhinav Deol, MD7 ; Mounzer Agha, MD8 ; Jesus G. Berdeja, MD9 ; Alexander M. Lesokhin, MD10; Jessica J. Liegel, MD11 ; Adriana Rossi, MD1 ; Alex Lieberman-Cribbin, MPH, CCRP1 ; Saad Z. Usmani, MD, MBA, FACP, FASCO10 ; Binod Dhakal, MD12 ; Samir Parekh, MD1 ; Hui Li, PhD13; Feng Wang, PhD13; Rocio Montes de Oca, PhD14 ; Vicki Plaks, PhD, LLB14; Huabin Sun, MD15; Arnob Banerjee, MD, PhD14; Jordan M. Schecter, MD15; Nikoletta Lendvai, MD, PhD15; Deepu Madduri, MD15; Tamar Lengil, PhD15; Jieqing Zhu, PhD16; Mythili Koneru, MD, PhD16; Muhammad Akram, MD16; Nitin Patel, BM BCh16; Octavio Costa Filho, MD16; Andrzej J. Jakubowiak, MD, PhD17 ; and Peter M. Voorhees, MD18 1Icahn School of Medicine at Mount Sinai, New York, NY 2University of California, San Francisco, San Francisco, CA 3Mayo Clinic, Rochester, MN 4Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 5Massachusetts General Hospital Cancer Center, Boston, MA 6Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, CA 7Karmanos Cancer Institute, Wayne State University, Detroit, MI 8UPMC Hillman Cancer Center, Pittsburgh, PA 9Tennessee Oncology, Nashville, TN 10Memorial Sloan Kettering Cancer Center, New York, NY 11Division of Hematologic Malignancies and Bone Marrow Transplantation, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 12Medical College of Wisconsin, Milwaukee, WI 13Johnson & Johnson, Shanghai, China 14Johnson & Johnson, Spring House, PA 15Johnson & Johnson, Raritan, NJ 16Legend Biotech USA Inc, Somerset, NJ 17University of Chicago, Chicago, IL 18Atrium Health/Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC
Previous Next